ERBB2 and ovarian cancer: CD8+ T cells expressing HER2 CAR T_shGCDH had significantly increased cytotoxicity against target HER2+ SKOV3 ovarian cancer cells when compared to control HER2 CAR T_shNTC cells (Fig. 5e).